Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial

离格 医学 放射治疗 肺癌 阶段(地层学) 打开标签 外科 薄壁组织 放射外科 内科学 放射科 肿瘤科 随机对照试验 癌症 病理 免疫疗法 古生物学 生物
作者
Joe Y. Chang,Steven H. Lin,Wenli Dong,Zhongxing Liao,Saumil Gandhi,Carl M. Gay,Jianjun Zhang,Stephen G. Chun,Yasir Y. Elamin,Frank V. Fossella,George R. Blumenschein,Tina Cascone,Xiuning Le,Jenny Vu Pozadzides,Anne S. Tsao,Vivek Verma,James W. Welsh,Aileen B. Chen,Mehmet Altan,Reza J. Mehran
出处
期刊:The Lancet [Elsevier BV]
卷期号:402 (10405): 871-881 被引量:121
标识
DOI:10.1016/s0140-6736(23)01384-3
摘要

Background Stereotactic ablative radiotherapy (SABR) is the standard treatment for medically inoperable early-stage non-small-cell lung cancer (NSCLC), but regional or distant relapses, or both, are common. Immunotherapy reduces recurrence and improves survival in people with stage III NSCLC after chemoradiotherapy, but its utility in stage I and II cases is unclear. We therefore conducted a randomised phase 2 trial of SABR alone compared with SABR with immunotherapy (I-SABR) for people with early-stage NSCLC. Methods We did an open-label, randomised, phase 2 trial comparing SABR to I-SABR, conducted at three different hospitals in TX, USA. People aged 18 years or older with histologically proven treatment-naive stage IA–IB (tumour size ≤4 cm, N0M0), stage IIA (tumour size ≤5 cm, N0M0), or stage IIB (tumour size >5 cm and ≤7 cm, N0M0) as per the American Joint Committee on Cancer version 8 staging system or isolated parenchymal recurrences (tumour size ≤7 cm) NSCLC (TanyNanyM0 before definitive surgery or chemoradiotherapy) were included in this trial. Participants were randomly assigned (1:1; using the Pocock & Simon method) to receive SABR with or without four cycles of nivolumab (480 mg, once every 4 weeks, with the first dose on the same day as, or within 36 h after, the first SABR fraction). This trial was unmasked. The primary endpoint was 4-year event-free survival (local, regional, or distant recurrence; second primary lung cancer; or death). Analyses were both intention to treat (ITT) and per protocol. This trial is registered with ClinicalTrials.gov (NCT03110978) and is closed to enrolment. Findings From June 30, 2017, to March 22, 2022, 156 participants were randomly assigned, and 141 participants received assigned therapy. At a median 33 months' follow-up, I-SABR significantly improved 4-year event-free survival from 53% (95% CI 42–67%) with SABR to 77% (66–91%; per-protocol population, hazard ratio [HR] 0·38; 95% CI 0·19–0·75; p=0·0056; ITT population, HR 0·42; 95% CI 0·22–0·80; p=0·0080). There were no grade 3 or higher adverse events associated with SABR. In the I-SABR group, ten participants (15%) had grade 3 immunologial adverse events related to nivolumab; none had grade 3 pneumonitis or grade 4 or higher toxicity. Interpretation Compared with SABR alone, I-SABR significantly improved event-free survival at 4 years in people with early-stage treatment-naive or lung parenchymal recurrent node-negative NSCLC, with tolerable toxicity. I-SABR could be a treatment option in these participants, but further confirmation from a number of currently accruing phase 3 trials is required. Funding Bristol-Myers Squibb and MD Anderson Cancer Center Alliance, National Cancer Institute at the National Institutes of Health through Cancer Center Core Support Grant and Clinical and Translational Science Award to The University of Texas MD Anderson Cancer Center.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小小一个应助和谐的梦蕊采纳,获得10
刚刚
刚刚
hhhuan完成签到,获得积分10
1秒前
2秒前
孟浩关注了科研通微信公众号
2秒前
晓天完成签到,获得积分10
3秒前
泽烺木完成签到,获得积分10
5秒前
落寞白曼完成签到,获得积分10
5秒前
人间不清醒完成签到,获得积分20
5秒前
欢欢发布了新的文献求助10
5秒前
快乐的奕涵完成签到,获得积分10
6秒前
zongzi12138完成签到,获得积分0
7秒前
7秒前
王哈哈完成签到,获得积分10
7秒前
香蕉觅云应助人间不清醒采纳,获得30
9秒前
12秒前
13秒前
bzdjsmw完成签到 ,获得积分10
13秒前
WebCasa应助旦皋采纳,获得10
13秒前
路易斯完成签到,获得积分10
14秒前
颜愫发布了新的文献求助10
14秒前
萌萌完成签到,获得积分10
15秒前
研友_X89o6n完成签到,获得积分10
17秒前
Ther发布了新的文献求助10
19秒前
哈哈哈完成签到,获得积分10
20秒前
22秒前
诚心的初露完成签到,获得积分10
22秒前
lyb完成签到 ,获得积分10
24秒前
风中方盒完成签到,获得积分20
24秒前
布丁圆团完成签到,获得积分10
25秒前
yikeshu完成签到,获得积分10
25秒前
Zoe完成签到 ,获得积分10
26秒前
28秒前
星辰大海应助do0采纳,获得10
29秒前
tt完成签到 ,获得积分10
30秒前
浅辰完成签到,获得积分10
31秒前
大气萤完成签到,获得积分20
32秒前
32秒前
我ppp完成签到 ,获得积分10
32秒前
33秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038368
求助须知:如何正确求助?哪些是违规求助? 3576068
关于积分的说明 11374313
捐赠科研通 3305780
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029